The SARM1 inhibitor market is projected to experience a remarkable compound annual growth rate (CAGR) of 102% in the forecast period, with the first product launch anticipated in 2033.

Across the world, there are more than 6.5 million deaths related to neurological disorders reported annually. Moreover, a United Nations (UN) report indicates that nearly one billion people globally are afflicted by various neurological disorders. The increasing prevalence of patients suffering from neurodegenerative conditions like peripheral neuropathy and multiple sclerosis has placed a significant strain on both the financial and resource aspects of the healthcare system. Notably, the annual expenditure for neurological disorder care in the US alone exceeded $ 655 billion in 2020. As the existing treatment options have proven to be largely inadequate, especially for neurological disorders characterized by axonal degeneration, there is a pressing demand for highly effective therapies targeting these conditions. Interestingly, Sterile Alpha and Toll/Interleukin-1 Receptor Motif-Containing 1 (SARM1), an NADase enzyme, has been identified as a crucial factor in triggering axonal degeneration, a central pathological feature in various neurodegenerative disorders.

At present, both industry and non-industry stakeholders are assessing the potential of SARM1 inhibitors as therapeutic agents for the treatment of neurological disorders like Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis in a multitude of preclinical studies and early stages of clinical development across the globe. Encouraged by promising research outcomes, players in the SARM1 inhibitor market have secured over USD 10 million in grants from various private and public organizations since 2014. Furthermore, numerous patents associated with SARM1 inhibitors have been recently filed or granted, underscoring the ongoing innovation in the SARM1 inhibitor market. With the pace of innovation persisting in the SARM1 inhibitor market, increased research and development activities, and auspicious preclinical data, several promising candidates are expected to make their commercial debut in the coming decade. As a result, the SARM1 inhibitor market is poised to undergo significant growth in the forecast period.

Key Market Segments
Target Indications

  • Multiple Sclerosis
  • Peripheral
  • Central and Ocular Nervous System Disorders
  • Peripheral Neuropathies
  • Glaucoma and Amyotrophic Lateral Sclerosis


Type of Molecule

  • Small Molecules
  • Biologics


Drug Developers

Drug Candidates

Geographic Regions

  • North America
  • Europe


Research Coverage:

  • The report studies the SARM1 inhibitor market by target indications, type of molecules, drug developers, drug candidates and key geographies.
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to major regions.
  • An overview of key findings from our research on the SARM1 inhibitor market, offering insights into its current state and likely evolution in the short, mid, and long term.
  • An introductory overview of SARM1 inhibitors therapeutics, providing insights into the role of the SARM1 pathway in neurodegenerative disorders, the mechanism of action of SARM1, and the means by which the SARM1 pathway can be inhibited.
  • A comprehensive examination of the current market landscape of SARM1 inhibitors therapeutics currently under investigation in pre-clinical studies, including an in-depth analysis of these therapies based on several key parameters. These parameters include the phase of development (preclinical and discovery), the type of molecule (small molecules and biologics), the target indication (unspecified neurological disorders, amyotrophic lateral sclerosis, multiple sclerosis, peripheral neuropathies, glaucoma, and peripheral, central, and ocular nervous system disorders), and the type of developers (industry and non-industry). This section also provides information about SARM1 inhibitor therapeutic developers, including analyses based on their year of establishment, company size, leading players (in terms of the number of SARM1 inhibitor candidates), and geographical locations.
  • An insightful analysis of the competitiveness of companies involved in the development of SARM1 inhibitors therapeutics, both industry and non-industry players. This analysis takes into account supplier strength, which is based on a company’s experience in the field, and company competitiveness, which is assessed based on the phase of development, target indications, and the type of molecule.
  • Detailed profiles of prominent players engaged in the evaluation of SARM1 inhibitors therapeutics, offering a concise overview of the company, its product portfolio, patent portfolio, recent developments, and a forward-looking perspective.
  • An extensive analysis of over 120 peer-reviewed scientific articles related to research on SARM1 inhibitors therapeutics over the last 12 years. This analysis is based on various parameters, including the year of publication, the type of publication, the most popular journals, popular keywords, active publishers, popular affiliations, and geographic distribution.
  • An in-depth examination of the grants received by participants in the SARM1 inhibitor market since 2014, taking into account factors such as the year of award, support period, amount awarded, funding institute, type of grant application, activity code, type of study section, purpose of the grant, prominent program officers, recipient organizations, popular NIH departments, and the location of recipient organizations.
  • A detailed analysis of the patents filed or granted related to SARM1 inhibitors therapeutics up to 2022, considering key parameters like the type of patent, publication year, application year, geographical region, CPC symbols, type of applicant, focus areas, patent age, and leading players (in terms of the size of their intellectual property portfolio). This section also includes a patent benchmarking analysis and a thorough evaluation of patent characteristics and valuation.
  • Information on recent developments, including partnerships, collaborations, funding, and investments, reported by various participants in the SARM1 inhibitor market.


Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the SARM1 inhibitor market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
  • You will get access to complimentary PPT insights and excel data packs / dynamic dashboards to easily navigate through complex analyses / charts.


Key Market Companies

  • Disarm Therapeutics
  • Nura Bio
  • Washington University